Taken together, all these data lead to the conclusion that targeting EZH2 by overexpression of miR‐124/506 or EPZ‐6438 treatment inhibits the proliferation ability of sorafenib resistant thyroid tumour cells via epigenetic regulation. This evidence concerns the gene EZH2 and thyroid tumor.